Ovarian cancer is the most lethal gynecologic malignancy in the United States. Some
patients affected by ovarian cancers often present genome instability with one or more of the …

Ovarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer
type overall in women. Ovarian cancer often presents genome instability, with almost half of …

Recent advances in our understanding of the molecular biology of epithelial ovarian cancer
have led to the development of a number of targeted therapies, including poly-ADP-ribose …

Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …

PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for
homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the …

Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as
antineoplastic agent> 20 years ago, only a few phase III randomized trials have shown …

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and
breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment …

Epithelial ovarian cancer (EOC) accounts for 90% of all ovarian cancer. Initially,
approaching 80% of EOC patients respond to standard therapeutic strategy, cytoreduction …

Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-
repair pathways. The proteins encoded by breast-related cancer antigen (BRCA) and poly …

Ovarian cancer continues to be the main cause of death among all gynecological tumors.
After standard treatments, most of patients are destined to recur within a short period, thus …